$1.78
6.93% today
Nasdaq, Oct 28, 04:20 pm CET
ISIN
US6963891055
Symbol
PALI

Palisade Bio Inc Stock price

$1.66
+0.74 80.10% 1M
+0.88 113.83% 6M
+0.01 0.61% YTD
-1.81 52.16% 1Y
-71.84 97.74% 3Y
-2,788.34 99.94% 5Y
-1,193,398.34 100.00% 10Y
-2,339,998.34 100.00% 20Y
Nasdaq, Closing price Mon, Oct 27 2025
-0.08 4.60%
ISIN
US6963891055
Symbol
PALI
Industry

Key metrics

Basic
Market capitalization
$203.1m
Enterprise Value
$198.0m
Net debt
positive
Cash
$5.4m
Shares outstanding
4.8m
Valuation (TTM | estimate)
P/E
- | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
77.5
Financial Health
Equity Ratio
68.9%
Return on Equity
-192.7%
ROCE
-
ROIC
-
Debt/Equity
0.1
Financials (TTM | estimate)
Revenue
- | $0.0
EBITDA
- | -
EBIT
- | $-13.2m
Net Income
- | $-8.4m
Free Cash Flow
$-9.7m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
- | -
EBIT
- | 11.3%
Net Income
- | 41.6%
Free Cash Flow
20.1%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
-
FCF per Share
$-2.0
Short interest
4.5%
Employees
8
Rev per Employee
$0.0
Show more

Is Palisade Bio Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,039 stocks worldwide.

Palisade Bio Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

9 Analysts have issued a Palisade Bio Inc forecast:

8x Buy
89%
1x Hold
11%

Analyst Opinions

9 Analysts have issued a Palisade Bio Inc forecast:

Buy
89%
Hold
11%

Financial data from Palisade Bio Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 5.80 5.80
6% 6%
-
- Research and Development Expense 9.06 9.06
31% 31%
-
-15 -15
16% 16%
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -15 -15
16% 16%
-
Net Profit -14 -14
17% 17%
-

In millions USD.

Don't miss a Thing! We will send you all news about Palisade Bio Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Palisade Bio Inc Stock News

Neutral
GlobeNewsWire
about 3 hours ago
Seasoned Pharmaceutical leader bringing over 24 years of experience in clinical development across autoimmune, metabolic, cardiovascular, and gastrointestinal indications
Neutral
PRNewsWire
8 days ago
NEW YORK , Oct. 20, 2025 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Palisade Bio, Inc. (NASDAQ: PALI) on behalf of the company's shareholders. The investigation seeks to determine whether Palisade Bio's directors breached their fiduciary duties in connection with recent corporate actions.
Neutral
GlobeNewsWire
8 days ago
First dual-acting anti-inflammatory and anti-fibrotic candidate in development for FSCD, a condition with no approved therapies
More Palisade Bio Inc News

Company Profile

Palisade Bio, Inc. is a biopharmaceutical company, which engages in the development of oral therapies that help patients with acute and chronic gastrointestinal complications stemming from post-operative digestive enzyme damage. It offers LB1148, an oral formulation of a broad-spectrum serine protease inhibitor designed to neutralize the activity of potent digestive proteases released from the gut during surgery. The company is headquartered in Carlsbad, CA.

Head office United States
CEO J. Finley
Employees 8
Founded 2011
Website palisadebio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today